ストックスクリーナーアプリを入手
5.82
5.14%
-0.02
前日終値:
$5.84
開ける：
$5.76
24時間の取引高:
96,712
Relative Volume:
2.02
時価総額：
$5.65M
収益：
-
当期純損益:
$-34.66M
株価収益率:
-0.0597
EPS:
-97.5284
ネットキャッシュフロー:
$-19.52M
1週間 パフォーマンス:
+7.78%
1か月 パフォーマンス:
-29.52%
6か月 パフォーマンス:
-35.66%
1年 パフォーマンス:
-23.27%
1日の値動き範囲:
$5.52
$6.30
1週間の範囲:
$3.82
$6.30
52週間の値動き範囲:
$3.82
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
5.95 | 5.55M | 0 | -34.66M | -19.52M | -97.53 |
VRTX
Vertex Pharmaceuticals Inc
|
452.94 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.10 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.57 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.71 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
150.50 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc (RNAZ) 最新ニュース
Exclusive: TransCode's RNA therapeutic achieves 64% stable disease rate in colorectal cancer phase 1 study - MSN
TransCode Therapeutics (RNAZ) Advances to Phase 2a Following Pos - GuruFocus
RNAZ | TransCode Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a - TipRanks
TransCode completes phase 1a trial of cancer drug TTX-MC138 By Investing.com - Investing.com Australia
TransCode Therapeutics (RNAZ) sees clean Phase 1a safety, 64% stable disease with TTX-MC138 - Stock Titan
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer - PR Newswire
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study - Yahoo Finance UK
TransCode Therapeutics (RNAZ) proxy bundles big equity, financing and director votes - Stock Titan
TransCode Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Nigeria
TransCode Sets Key Deadlines for 2026 Shareholder Meeting - TipRanks
TransCode Therapeutics, Inc. Files Form 8-K with NASDAQ Listing and Company Details (RNAZ) - Minichart
TransCode Therapeutics (RNAZ) sets July 2, 2026 annual meeting and June 11 proposal cutoff - Stock Titan
(RNAZ) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease - citybuzz -
TransCode initiates phase 2a trial for colorectal cancer drug By Investing.com - Investing.com Australia
TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 in Patients With CtDNA Positive Colorectal Cancer - Moomoo
TransCode Therapeutics (RNAZ) Drops 10.66%: Support at $5.3 Faces Critical Test After Sharp DeclineCTA Positioning - The Legal Advocate
TransCode Therapeutics Files 8-K/A Detailing Nasdaq Compliance Plan and Soliciting Material Disclosure - Minichart
Nasdaq warns TransCode (NASDAQ: RNAZ) on equity shortfall and delisting risk - Stock Titan
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice - TipRanks
TransCode Therapeutics (RNAZ) Surges 2% as Biotech Stock Tests Key Resistance at $6.55Head and Shoulders - Newser
TransCode Therapeutics (NASDAQ: RNAZ) warned on Nasdaq equity shortfall - Stock Titan
[EFFECT] Transcode Therapeutics, Inc. SEC Filing - Stock Titan
What TransCode Therapeutics RNAZ flagged as biggest challenges ahead Q4 2024 Below ExpectationsQuarterly Earnings - Newser
TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Transcode Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Mesa Air Group, Inc.Common Stock (NQ: MESA - FinancialContent
What you need to know before buying TransCode Therapeutics (RNAZ) (Breakdown Watch) 2026-05-11Fast Rising Picks - newser.com
What TransCode Therapeutics (RNAZ) flagged as biggest challenges ahead | Q4 2024: Below ExpectationsHigh Interest Stocks - newser.com
Trading Systems Reacting to (RNAZ) Volatility - Stock Traders Daily
TransCode Therapeutics (RNAZ) asks shareholders to OK preferred conversions, SEPA funding - Stock Titan
How TransCode Therapeutics (RNAZ) differentiates itself from competitors (Near Highs) 2026-05-08Open Stock Signal Network - newser.com
TransCode Therapeutics 2025 10-K/A: Executive Compensation, Board Members, and Corporate Governance Overview - Minichart
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership - Stock Titan
MSN Money - MSN
TransCode names Anna Moore scientific board chair - Investing.com UK
TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University - citybuzz -
TransCode names Anna Moore scientific board chair By Investing.com - Investing.com Australia
Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board - marketscreener.com
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - PR Newswire
RNAZ News | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
RNAZ (TransCode Therapeutics Inc.) posts far wider than expected Q4 2024 loss, shares notch small gain in today’s trading.Asset Sale - Xã Thanh Hà
TransCode Therapeutics (RNAZ) Stock: Volatility Overview (-4.45%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note - Stock Titan
(RNAZ) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TransCode Therapeutics 2025 10-K: Advancing RNA and Immuno-Oncology Cancer Therapeutics with Proprietary TTX Platform - Minichart
Transcode Therapeutics Inc (RNAZ) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
0.82%
大文字化:
|
ボリューム (24 時間):